An MCID for AIMS Dyskinesia Total Score Change in Subjects with Tardive Dyskinesia
Objective: To establish a minimal clinically important difference (MCID) for Abnormal Involuntary Movement Scale (AIMS) dyskinesia total score change using data from randomized, double-blind, placebo…Tardive Dyskinesia by Body Region in Subjects with Schizophrenia/Schizoaffective Disorder or Mood Disorder: Findings from the KINECT 3 Study
Objective: To characterize dyskinesia distribution by body region in subjects with tardive dyskinesia (TD) enrolled in a clinical trial of valbenazine, based on baseline Abnormal…Exploring aging-VMAT2 gene-rotenone interactions in a cell model for Parkinson’s disease
Objective: To develop a Parkinson's disease (PD) model based on aging, vesicular monoamine transporter 2 (VMAT2) gene susceptibility and chronic rotenone exposure in SK-N-SH cell,…Cognitive and depressive behavior changes in aged mice with heterozygous deletions of VMAT2 or of DAT
Objective: To evaluate cognitive and depressive behavior in aged mice with heterozygous deletions of vesicular monoamine transporter (VMAT2) or of Dopamine transporter (DAT). Background: VMAT2…A pilot study of SD-809 (deutetrabenazine) in tics associated with Tourette syndrome
Objective: This study explored the safety, tolerability and preliminary efficacy of SD-809 (deutetrabenazine) in adolescents with moderate to severe tics associated with Tourette syndrome (TS).…KINECT 3: A randomized, double-blind, placebo-controlled phase 3 trial of valbenazine (NBI-98854) for tardive dyskinesia
Objective: To assess the efficacy, safety and tolerability of valbenazine (NBI-98854) for Tardive Dyskinesia (TD). Background: Tardive dyskinesia (TD) is a persistent and often disabling…
- « Previous Page
- 1
- …
- 3
- 4
- 5